Selpercatinib Approved for RET-Mutant NSCLC, Thyroid Cancer

The FDA has approved selpercatinib (RetevmoTM, Eli Lilly), for adult patients with metastatic RET-fusion—positive NSCLC, adult and pediatric patients 12 years of age or older with advanced or metastatic RET-mutant medullary thyroid cancer (MTC) who require systemic therapy, and adult and pediatric patients 12 years of age or older with advanced or metastatic RET-fusion—positive thyroid cancer who require systemic therapy and are refractory to radioactive iodine. Selpercatinib is the first treatm...
Continue reading

Metastatic Breast Cancer: Palbociclib Now Approved for Men

​The FDA has now expanded the indication for palbociclib (Ibrance®, Pfizer Inc.) in combination with an aromatase inhibitor or fulvestrant (Faslodex®, AstraZeneca) to include men with hormone receptor (HR)-positive, human epidermal growth factor receptor 2 (HER2)-negative advanced or metastatic breast cancer. Because breast cancer in men is rare, comprising less than 1% of all breast cancer cases, men with breast cancer are more likely to be diagnosed at an older age and with a more advanced sta...
Continue reading

Copyright © 2020 Oncology Data Advisor. All rights reserved.